Loading
German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma.
Ralf Gutzmer is a German dermato-oncologist who led skin cancer research at Hannover Medical School before moving to the Mühlenkreiskliniken in Minden. He was first author of the 2020 Lancet report of IMspire150, the phase 3 trial in which atezolizumab plus vemurafenib and cobimetinib lengthened progression-free survival compared with the two targeted drugs alone in untreated BRAF V600-mutant advanced melanoma, the first approval of a triplet combining immunotherapy and BRAF-MEK inhibition.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, trialist.
Shares Melanoma and the tags melanoma, immunotherapy, trialist.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, immunotherapy.
Shares Melanoma and the tags melanoma, trialist.
Shares Melanoma and the tags melanoma, immunotherapy.